This ALONE, is one of the most interesting & factual reasons for owning a few shares of this company; if for no other reason.
The final sentence in the article clearly states the reason for the article & the reason for the study:
"the first step is to determine whether the drug has an effect on the disease, which is the primary goal of this study"..
I, for one, am not trying to read between the lines. Based on the ongoing tests, if results are favorable simply means that more testing will then need to be funded & started.
WHO is selling, or for WHAT reason is merely conjecture/wishful thinking/rumor; the only thing that REALLY counts are the text results of P2 in Sep-Oct time frame.
Like most all BioTech stocks, GALT is going to need to raise more money, at some point in the future, to fund P3 tests, IF P2 test results are favorable.......or partner with another company that will provide the money.
There is an old wall street adage; Sell in May & go away. I'm NOT selling, however, I'm also NOT buying any more shares, I have my long-term position set. For MEeee, I see no reason to check the stock price daily or even weekly until late September, so perhaps I'm "going away"
I DISAGREE. I think GALT already has an agreement with Exalenz, the Israeli company that approached GALT & offered their non-invasive test equipment. IF P2 test data that will be published at the end of Q3 is favorable, I strongly suspect EXEL & GALT will further their business agreement by giving them advance notice of the test results so they can buy up GALT stock at low prices. In return, GALT will get the money they need for P3. This is just my opinion.
I hope you're right, however today's share volume is UNUSUALLY low. Very, very few shares have traded today. That doesn't sound/look like what I'd expect if "someone knows something"
with only 30 minutes remaining in the trading day, only a little more than 23,000 shares have traded. This is an unusually LOW number of shares traded. CNAT is another biotech with unusually LOW volume today.
I just received an email from Galectin Therapeutics, which is as follows:
We are pleased to alert you to news that Galectin Therapeutics and Peter Traber, M.D., the Company’s president, chief executive officer and chief medical officer, were profiled on HealthZette, an on-line health-related magazine, in a story entitled, “The New Liver Killer: Silent, Sneaky, Deadly.”
You can find this article on the web at: The New Liver Killer: Silent, Sneaky, Deadly
Yahoo doesn't allow live links in topics/replies; you know what you need as a prefix & suffix to LIFEZETTE
This is the 2nd time in several months where Dr. Traber has been sought out by the publishers of magazines & interviewed for articles dealing with Liver Disease.
You can get these occasional emails from Galectin Therapeutics by signing up for them on their website.
Dr Traber's article can be read by going to Galectin Therapeutics website. All of his articles should be read by shareholders, prospective investors, & YOU.
I've read you comments on the CNAT message board which are thoughtful & well reasoned.
I, too, hold shares in GALT & CNAT, because I believe they are both onto something good. I still consider both to be a #$%$ shoot; it's still possible for one or both to turn out to be worthless.
I'll look forward to your replies on both message boards from now on.
Hopefully, CNAT ends the day with millions of shares being traded & closing at a price of $4.00 or higher
I hope the following gives you a better understanding of PASI scores:
How PASI Score Works
This tool allows researchers to put an objective number on what would otherwise be a very subjective idea: how bad is a person's psoriasis. To make up the score, the three features of a psoriatic plaque (redness) scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. Then the extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72.
Improving PASI Score
Many studies quote the improvement seen in the PASI score over time as a measure of a drug's effectiveness. For example, they may note that a certain proportion of patients experienced a 75 percent reduction in their PASI scores over a 12-week treatment period and report this as a percentage of people achieving "PASI 75."
PASI scores are seldom used in clinical practice, although more fastidious doctors or those working at university-based clinics or specialized psoriasis treatment centers may routinely use this tool to follow their patients' progress.
I looked it up on the internet & now know. However, others may not & they might like clarification on the abbreviation of PASI
EASL conference is ongoing right now; 13-17 April. Thursday & Today's increase in the closing price, plus 3 times more trading volume both days is higher than normal, is telling me that someone from GALT said something, to some people that got their attention & may have resulted in some people buying a few shares of stock.. This is merely conjecture on my part.
It is comforting to see a pattern since early March of consistent/orderly higher lows & higher highs. Equally comforting is knowing my position is now showing a paper profit, anything above $1.60 is plus territory for me.
Giguy, I'll have to disagree, in part, with your opinion that psoriasis is a complete side show. In comparison to reversing fibrosis in late state liver disease is the big enchilada, psoriasis is definitely 2nd fiddle in terms of marketing dollars, however is the psoriasis trials/data/tests are positive I'm thinking it should move GALT stock price higher; which may mean fewer shares needing to be sold with what is surely an upcoming & needed secondary offering/private placement. A GALT price AFTER psoriasis of $5.00-$6.00 I would thing would be more attractive to prospective investors that a stock selling between $1.00-$3.00. Again, this is just my observation & opinion
I believe $1.50 is now a solid support level; meaning more near term upside potential than downside risk.
My notion of support & resistance levels sure got shot down today. Looks like $1.50 is again a RESISTANCE level, meaning there is now more downside risk than upside potential.....in my opinion.
Can anyone else come up with additional, "Also in favor of GALT" notions/reasons/ideas?
Also in favor of GALT is their multiple non-invasive testing methods; they're not relying just on biopsy.
YES, I know these non-invasive testing methods don't have FDA approval, however it is good thinking to have these non-invasive test results IF they are positive, just in case the biopsy is negative.
Also in favor of GALT is they're apparent strong patent protection, at least it seems like they are making every effort to protect GR-MD-02 from being copied.
Also in favor of GALT, is Exalenz, an Israeli test equipment maker that approached GALT & offered their equipment to GALT for non-invasive testing of patients
Also in favor of GALT is the Newsweek article that approached Dr Traber
Also in favor of GALT is several INVITATIONS to prestigious Liver Conferences
Also in favor of GALT is the relatively recent uptrend in stock price.accompanied by higher than normal volume.
I've got my fingers crossed.
I'm not as confident as you that the Q3 results will be as conclusively positive as you seem to be.
Is it possible, GALT could call off the P2 trials IF things aren't working out in human trials?
Am I missing something here? Generally speaking, test results seldom live up to investor HOPES. This is just my opinion; Yes, I am a shareholder & am HOPING for the best possible test results, but am hoping with a healthy dose of reality.
Giguy hit the nail on the head when he recently said all we know for sure about GALT is that GR-MD-02 has worked with mice, according to GALT and that GALT is still a long-shot so don't put any money into the stock you can't afford to lose.
If the P2 trials, for any reason are postponed, or called off, then this stock will open, GAP DOWN after the news which surely will be released after the close of business & will quickly fall to less than $1.00 a share.
The way things are shaping up, IF a Liver compound DOESN'T REVERSE FIBROSIS, it won't have any realistic commercial profits.